Chargement en cours...
The Evolving Immunotherapy Landscape and the Epidemiology, Diagnosis, and Management of Cardiotoxicity: JACC: CardioOncology Primer
Immune checkpoint inhibitors (ICIs) are newer therapies being applied to an increasing number of patients with cancer. Data suggest that up to 36% of cancer patients may be eligible for immunotherapy and, in late 2019, there were more than 3,362 clinical trials initiated to evaluate the effectivenes...
Enregistré dans:
| Publié dans: | JACC CardioOncol |
|---|---|
| Auteurs principaux: | , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Elsevier
2021
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8034586/ https://ncbi.nlm.nih.gov/pubmed/33842895 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jaccao.2020.11.012 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|